As of Q4'25, BAC's latest reported SG&A Expenses stand at USD 17.44B, while R&D Expenses remain at USD 0. This marks the highest SG&A expense level in the observed period from Q1'23 to Q4'25. Throughout the period, SG&A Expenses exhibited moderate fluctuations, starting at USD 13.65B in Q1'23, dipping slightly in mid-2023, and peaking sharply in Q4'23 and Q4'25. Notably, there were significant increases in Q4 of each year, suggesting a recurring seasonal or annual uptick. R&D Expenses consistently registered at USD 0, indicating no allocation to this category during the entire timeframe.